This is an aussie company traded on the aussie exchange as AVH and in the US pink sheets as AVMXF. Their quarterly report shows just under $1mil in revenues with substantial losses.
They do not yet have FDA approval in the US but is conducting clinical trials. If they're smart, they'll sell their tech to a larger US firm for distribution.
They do not yet have FDA approval in the US but is conducting clinical trials. If they're smart, they'll sell their tech to a larger US firm for distribution.